CD20 Antibody

Biorbyt

CD20 Antibody

16

Optimal dilution of the antibody should be determined by the researcher.

ELISA: 2-4ug/ml (order BSA/azide-free format),Flow cytometry: 1-2ug/million cells,Immunofluorescence: 1-2ug/ml,Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 0.5-1ug/ml for 30 min at RT ELISA, FACS, IF, IHC-P, WB

Research Use Only

Monoclonal

MS4A1/3409

Unconjugated

MS4A1

membrane spanning 4-domains A1

B1; B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; Bp35; CD20; CD20 antigen; CD20 receptor; CVID5; FMC7; LEU-16; leukocyte surface antigen Leu-16; membrane-spanning 4-domains, subfamily A, member 1; S7

Mouse

IgG2b

B-lymphocyte antigen CD20

Recognizes a protein of 30-33kDa, which is identified as CD20. It is a non-Ig differentiation antigen of B-cells and its expression is restricted to normal and neoplastic B-cells, being absent from all other leukocytes and tissues. CD20 is expressed by pre-B-cells and persists during all stages of B-cell maturation but is lost upon terminal differentiation into plasma cells. This MAb can be used for immunophenotyping of leukemia and malignant cells, B lymphocyte detection in peripheral blood and B cell localization in tissues. It reacts with the majority of B-cells present in peripheral blood and lymphoid tissues and their derived lymphomas. In lymphoid tissue, germinal center blasts and B-immunoblasts are particularly reactive. It is a reliable antibody for ascribing a B-cell phenotype in known lymphoid tissues. Rarely, CD20-positive T-cell lymphomas have been reported. Reactivity has also been noted with Reed-Sternberg cells in cases of Hodgkins disease, particularly of lymphocyte predominant type.

Human

-20°C,2°C to 8°C

12352203